Ubs Group Ag Bellerophon Therapeutics, Inc. Transaction History

Ubs Group Ag

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 08, 2023	BUY	$0.67 - $1.2 $1,538 - $2,756	2,297 New	2,297 $2,000
Q2 2022 Aug 10, 2022	SELL	$0.85 - $2.36 $2,185 - $6,067	-2,571 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.82 - $3.24 $638 - $1,137	351 Added 15.81%	2,571 $6,000
Q4 2021 Feb 14, 2022	BUY	$2.36 - $4.05 $2,475 - $4,248	1,049 Added 89.58%	2,220 $7,000
Q3 2021 Nov 15, 2021	SELL	$3.75 - $4.86 $8,212 - $10,643	-2,190 Reduced 65.16%	1,171 $4,000
Q2 2021 Aug 13, 2021	BUY	$3.83 - $5.65 $4,818 - $7,107	1,258 Added 59.82%	3,361 $16,000
Q1 2021 May 12, 2021	BUY	$5.07 - $8.27 $2,281 - $3,721	450 Added 27.22%	2,103 $11,000
Q4 2020 Feb 11, 2021	SELL	$6.12 - $10.37 $2,919 - $4,946	-477 Reduced 22.39%	1,653 $11,000
Q3 2020 Nov 12, 2020	BUY	$9.27 - $13.79 $9,677 - $14,396	1,044 Added 96.13%	2,130 $22,000
Q2 2020 Jul 31, 2020	BUY	$9.43 - $20.28 $1,810 - $3,893	192 Added 21.48%	1,086 $14,000
Q1 2020 May 01, 2020	BUY	$3.39 - $18.0 $3,030 - $16,092	894 New	894 $10,000

44K

Ticker BLPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 9,545,450
Market Cap $382K
Description
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.